SCHEMBL303389

SCHEMBL303389

C1CC2(CCN1)CCNC2

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
CYP2D6 P10635 3/20 0.33
USP2 O75604 2/20 0.33
HIF1A Q16665 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPT P10636 1/20 0.33
PDE4A P27815 1/20 0.33
KDR P35968 1/20 0.33
HTR2A P28223 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP3A4 P08684 2/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CRBN Q96SW2 1/20 0.31
L3MBTL3 Q96JM7 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27184132 0.97 TSHR (0.40) TSHRCYP2D6USP2HIF1AALDH1A1
SCHEMBL16877427 0.94 TSHR (0.39) TSHRCYP2D6USP2HIF1AALDH1A1
SCHEMBL343237 0.93
Hydrochloric Acid SCHEMBL15537634 0.90
Bromide SCHEMBL29750142 0.90
SCHEMBL5431066 0.90 TSHR (0.40) TSHRCYP2D6USP2HIF1AALDH1A1
SCHEMBL473625 0.89
SCHEMBL16877552 0.88 TSHR (0.36) TSHRCYP2D6USP2HIF1AALDH1A1
SCHEMBL503843 0.88 ALDH1A1 (0.39) TSHRCYP2D6USP2ALDH1A1HPGD
SCHEMBL5438795 0.88 ALDH1A1 (0.39) TSHRCYP2D6USP2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 EP claimed
EP-4648763-A2 COMPOUNDS FOR FGFRS INHIBITORS Cogent Biosciences, Inc. (US) 2025-11-19 EP claimed
EP-4646263-A1 SPRK1 INHIBITORS AND METHODS OF USE Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2025-11-12 EP claimed
US-20250263412-A1 NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-08-21 US claimed
EP-4590672-A1 PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 Merck Sharp & Dohme LLC (US) 2025-07-30 EP claimed
CN-119907797-A Phthalazine derivatives as NOD-like receptor protein 3 inhibitors 默沙东有限责任公司 2025-04-29 CN claimed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US claimed
CN-119768392-A Aryl or heteroaryl substituted glutarimide derivatives and uses thereof 标新生物医药科技(上海)有限公司 2025-04-04 CN claimed
CN-119654316-A Thioglutarimide isoindolinone skeleton-based compound and application thereof 标新生物医药科技(上海)有限公司 2025-03-18 CN claimed
CN-119451952-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione derivative and application thereof 标新生物医药科技(上海)有限公司 2025-02-14 CN claimed
EP-0479631-B1 Spiro[4,5]decane derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1994-11-02 EP claimed
EP-0243645-B1 Compounds having a nootropic activity, agents containing them and their use in the treatment and prophylaxis of cognitive malfunctions HOECHST AG (DE) 1994-03-16 EP claimed
EP-0566069-A1 Tachykinin receptor antagonists, isoquinolones and their production TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-10-20 EP claimed
EP-0219782-B1 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN THE TREATMENT OF ATHEROSCLEROSIS, THROMBOSIS AND PERIPHERAL VASCULAR DISEASE HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-29 EP claimed
EP-0529688-A2 Azaspiro n,m alkanes and diazaspiro n,m -alkanes DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP claimed
EP-0265685-B1 COMBINATION OF ACE INHIBITORS WITH CALCIUM ANTAGONISTS, AND THEIR USE IN MEDICINES HOECHST AKTIENGESELLSCHAFT (DE) 1992-07-29 EP claimed
EP-0479631-A1 Spiro[4,5]decane derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1992-04-08 EP claimed
EP-0135181-B1 PROCESS FOR THE PRODUCTION OF N-ALKYLATED DIPEPTIDES AND OF THEIR ESTERS HOECHST AKTIENGESELLSCHAFT (DE) 1990-01-31 EP claimed
EP-0126986-B1 PROCESS FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS HOECHST AKTIENGESELLSCHAFT (DE) 1987-08-05 EP claimed
US-4525301-A REACTING TRIFLUOROMETHANE SULFONIC ACID DERIVATIVES WITH AMINO ACID ESTERS HOECHST AKTIENGESELLSCHAFT (DE) 1985-06-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR TSHR 277/4885CYP2D6 1436/4885USP2 3238/4885
US-20250263412-A1 NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE HDAC6, HHAT, HDAC1 TSHR 1636/4885CYP2D6 3822/4885USP2 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.